7 Citations (Scopus)


Background: Curcumin is a polyphenol natural product of the plant Curcuma longa. Recent studies suggest that curcumin inhibit mTOR activity in vitro, which prompts us to investigate curcumin function as a new class of mTOR inhibitor suitable for tuberous sclerosis complex (TSC) treatment. Purpose: We aim to investigate the efficacy of curcumin in the treatment of TSC related manifestations in animal model. Study Design: Solid lipid curcumin particle (SLCP), a novel curcumin formulation, was used to treat TSC related manifestations in Tsc2 knockout mice. Methods: The novel object recognition test was used to analyze the recognition memory function. The long-term potentiation was studied using electrophysiological analysis. Western blotting was used to assess the protein expression and activation status. Results: Recognition memory deficit began as early as 4 weeks of age in both male and female Tsc2+/− mice. Oral administration with SLCP activates AMPK activity and inhibits mTOR activity in the brain tissue of Tsc2+/− mice, and can rescue the electrophysiological abnormality and object recognition memory loss in the mice. Conclusions: Our results suggest that SLCP could be an effective treatment for TSC patients.

Original languageEnglish
Pages (from-to)132-139
Number of pages8
Publication statusPublished - Feb 15 2019


  • Curcumin
  • Solid lipid curcumin particle
  • Tuberous sclerosis complex

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Pharmaceutical Science
  • Drug Discovery
  • Complementary and alternative medicine


Dive into the research topics of 'Potential therapeutic effect of curcumin, a natural mTOR inhibitor, in tuberous sclerosis complex'. Together they form a unique fingerprint.

Cite this